Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

On August 31, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that management will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference (Press release, Compugen, AUG 31, 2023, https://www.prnewswire.com/news-releases/compugen-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301914569.html [SID1234634814]). The presentation will be available on demand on the Investor Relations section of Compugen’s website at www.cgen.com from Monday, September 11, 2023, 7:00 AM ET for 30 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!